News

Linnaeus Therapeutics Appoints Tina Garyantes, Ph.D., to Senior Vice President of Research and Development Haddonfield NJ, September 1, 2018--Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company [...]

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that it has closed a $4.4 million series A financing. Kairos Ventures, of Beverly Hills, California, led the financing with significant participation from the University of Pennsylvania, Linnaeus CEO, Patrick Mooney, and Linnaeus SVP, R&D, Tina Garyantes.

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that preclinical data from studies conducted at the University of Pennsylvania by its scientific founders was published in the journal eLife.

Linnaeus Therapeutics Awarded $300,000 Phase 1 STTR by National Cancer Institute Haddonfield NJ, March 16, 2018--Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the [...]

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that data from studies conducted at the University of Pennsylvania by its scientific founders was published in the journal eLife.